Argelaguer Vall del Llierca

Garrotxa: Argelaguer – Tortellà – Montagut i Oix – Sales de Llierca – Sant Jaume de Llierca – Fundat l´any 2005

Toyobo Co. Ltd. ha comprat l’empresa de la Garrotxa Spinreact SAU

Posted by lejarza en 3 agosto, 2013


Toyobo Co. Ltd. ha comprat l’empresa de la Garrotxa Spinreact SAU

Vall del Llierca, Argelaguer – Sant Esteve d’en Bas – Garrotxa

Toyobo Co. Ltd. ha comprat l’empresa garrotxina de bioquímica Spinreact SAU fundadà l´any 1975, amb seu a Sant Esteve d’en Bas, per 3.000 milions de yens, 22,8 milions d’euros amb la finalitat d’expandir-se, segons informa el diari Nikkei, Toyobo va adquirir el cent per cent de les accions que eren propietat de la companyia Alere Inc. Spinreact S. A. es dedica a la fabricació de reactius per a anàlisis clíniques que permeten, entre d’altres, la realització de tests d’embaràs o de consum de drogues. 
A través d’un comunicat, Toyobo va apuntar que l’operació es va tancar el 31 de juliol i que amb ella pretén “accelerar substancialment la seva estratègia d’expansió a l’estranger al camp de la biotecnologia”.
En aquest sentit, va recordar que l’empresa gironina, que va tancar el 2012 amb una facturació de més de 22 milions d’euros, té una xarxa de negoci en aproximadament 90 països a tot el món, així com una sèrie de productes relacionats amb el diagnòstic in vitro que han estat adaptats per al seu ús en mercats emergents.
A més, la companyia amb seu a Osaka pretén usar les instal·lacions de Spinreact i desenvolupar de manera conjunta nous productes.

Anuncios

Una respuesta to “Toyobo Co. Ltd. ha comprat l’empresa de la Garrotxa Spinreact SAU”

  1. lejarza said

    Toyobo Acquires Spain’s Spinreact S.A., a Global Manufacturer and Marketer of Diagnostic Reagents and Instruments ––Marking the Acceleration of Toyobo’s Overseas Expansion Strategy in Biotechnology––

    Toyobo purchased 100% of the shares of Spinreact, S.A. (hereinafter, Spinreact), which manufactures in vitro diagnostic (IVD) reagents and instruments and markets these products through its global network. The purchase was completed on July 31, 2013, and all the shares were purchased from the corporate group of U.S. company Alere Inc. (NYSE: ALR). Following the acquisition of Spinreact, Toyobo will substantially accelerate its strategy of overseas expansion in the field of biotechnology.

    1. Background of the Acquisition
    Toyobo, as a company aiming to be “the category leader , continuing to create new value that contributes to society in the environment, life science, and high-function products fields,” has set the objectives of being a “strong company” that can grow and develop sustainably and that can contribute to societies around the world through its business activities. In the Biotechnology field, where Toyobo is focusing on IVD reagents and instruments as well as other products, overseas, mainly in the emerging countries, markets are forecast to expand at more than 10% annually. To expand sales in overseas markets, Toyobo has been considering alliances and M&A with overseas companies.
    Given these circumstances, Toyobo acquired Spinreact, which has a network of dealers in approximately 90 countries around the world, covering not only Spain but also Africa, Central and South America, Europe, Asia, and elsewhere as well as an extensive lineup of IVD-related products that have been adapted for use in the emerging country markets.

    2. Toyobo’s objectives in Acquiring Spinreact as a Wholly Owned Subsidiary
    (1) To utilize Spinreact’s global sales network
    In the field of IVD reagents and instruments, Toyobo will use Spinreact’s sales network to market its biochemical diagnostic agents, which are one of its strengths, as well as its urine analysis and gene analysis systems that are based on Toyobo’s advanced image processing and ultra high-speed PCR technology
    (2) To expand its product lineup.
    Toyobo will market Spinreact’s biochemical, immunology, and serology diagnostic reagents through Toyobo’s sales network in China and Southeast Asia.
    (3) To secure a production base in Europe
    Toyobo will draw on Spinreact’s production capabilities in Europe to develop its overseas bioproducts business.
    3. Confirmed Acquisition Date: July 31, 2013
    4. Outlook Going Forward
    Going forward, Toyobo and Spinreact will use their bioproducts and sales networks to expand existing businesses. Next, the two companies will combine their biotechnologies to develop new products and expand into new markets.
    5. Supplementary Information
    (1)Outline of Spinreact S.A.
    Location of the head office: Girona, Spain
    Date of establishment: 1975
    Representative: Josep Puig (General Manager)
    Lines of business: Sales, manufacturing and developing of IVD reagents
     
    For more information, contact:
    The Toyobo Public Relations Group
    pr_g@toyobo.jp

Responder

Introduce tus datos o haz clic en un icono para iniciar sesión:

Logo de WordPress.com

Estás comentando usando tu cuenta de WordPress.com. Cerrar sesión / Cambiar )

Imagen de Twitter

Estás comentando usando tu cuenta de Twitter. Cerrar sesión / Cambiar )

Foto de Facebook

Estás comentando usando tu cuenta de Facebook. Cerrar sesión / Cambiar )

Google+ photo

Estás comentando usando tu cuenta de Google+. Cerrar sesión / Cambiar )

Conectando a %s

 
A %d blogueros les gusta esto: